PL2379586T3 - Onkolityczne wektory adenowirusowe i związane z nimi sposoby i zastosowania - Google Patents

Onkolityczne wektory adenowirusowe i związane z nimi sposoby i zastosowania

Info

Publication number
PL2379586T3
PL2379586T3 PL09796016T PL09796016T PL2379586T3 PL 2379586 T3 PL2379586 T3 PL 2379586T3 PL 09796016 T PL09796016 T PL 09796016T PL 09796016 T PL09796016 T PL 09796016T PL 2379586 T3 PL2379586 T3 PL 2379586T3
Authority
PL
Poland
Prior art keywords
methods
adenoviral vectors
uses related
oncolytic adenoviral
oncolytic
Prior art date
Application number
PL09796016T
Other languages
English (en)
Inventor
Akseli Hemminki
Anna Kanerva
Vincenzo Cerullo
Sari Pesonen
Original Assignee
Targovax Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20080671A external-priority patent/FI20080671A0/fi
Application filed by Targovax Oy filed Critical Targovax Oy
Publication of PL2379586T3 publication Critical patent/PL2379586T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL09796016T 2008-12-22 2009-12-21 Onkolityczne wektory adenowirusowe i związane z nimi sposoby i zastosowania PL2379586T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FI20080671A FI20080671A0 (fi) 2008-12-22 2008-12-22 Onkolyyttiset virukset
FI20095466A FI121508B (fi) 2008-12-22 2009-04-27 Adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä
US58597109A 2009-09-29 2009-09-29
EP09796016.5A EP2379586B1 (en) 2008-12-22 2009-12-21 Oncolytic adenoviral vectors and methods and uses related thereto

Publications (1)

Publication Number Publication Date
PL2379586T3 true PL2379586T3 (pl) 2017-08-31

Family

ID=44502296

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09796016T PL2379586T3 (pl) 2008-12-22 2009-12-21 Onkolityczne wektory adenowirusowe i związane z nimi sposoby i zastosowania

Country Status (20)

Country Link
EP (1) EP2379586B1 (pl)
JP (2) JP2012513209A (pl)
KR (1) KR101761094B1 (pl)
CN (1) CN102264760B (pl)
AU (1) AU2009332883B2 (pl)
BR (1) BRPI0924123B8 (pl)
CA (1) CA2748180C (pl)
CY (1) CY1120039T1 (pl)
DK (1) DK2379586T3 (pl)
ES (1) ES2612889T3 (pl)
HR (1) HRP20170165T1 (pl)
HU (1) HUE031689T2 (pl)
LT (1) LT2379586T (pl)
PL (1) PL2379586T3 (pl)
PT (1) PT2379586T (pl)
RU (1) RU2520823C2 (pl)
SG (1) SG173432A1 (pl)
SI (1) SI2379586T1 (pl)
WO (1) WO2010072900A1 (pl)
ZA (1) ZA201104224B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2836117C (en) 2009-12-10 2017-08-15 Ottawa Hospital Research Institute Oncolytic rhabdovirus
EP2619312A1 (en) * 2010-09-24 2013-07-31 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
AU2011306846B2 (en) * 2010-09-24 2015-05-14 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
DK2806883T3 (da) 2012-01-25 2019-07-22 Dnatrix Inc Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation
EP2958994B1 (en) 2013-02-21 2019-05-29 Turnstone Limited Partnership Vaccine composition
JP6576326B2 (ja) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍溶解性アデノウイルス組成物
RU2539764C2 (ru) * 2013-04-02 2015-01-27 Общество С Ограниченной Ответственностью "Ива" Универсальные раковоспецифичные промоторы и их использование в противоопухолевой терапии
BR112015026417B1 (pt) * 2013-04-18 2024-02-27 Tilt Biotherapeutics Oy Usos de um vetor adenoviral oncolítico que codifica pelo menos uma citocina, e uma composição terapêutica de célula adotiva separada, kit farmacêutico, vetores adenovirais oncolíticos, composição farmacêutica
US10350275B2 (en) * 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
CA2985029A1 (en) * 2015-05-04 2016-11-10 Vcn Biosciences Sl Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment
FI127460B (en) * 2016-01-15 2018-06-29 Targovax Oy COMBINATION OF ADENOVIRUS AND CHEMOTHERAPY AGENTS FOR CANCER CARE
KR20180112024A (ko) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
JP7208492B2 (ja) 2016-03-10 2023-01-19 シージー オンコロジー， インコーポレイテッド 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
ES2845690T3 (es) 2016-09-12 2021-07-27 Targovax Oy Combinación de adenovirus e inhibidores de punto de control para el tratamiento del cáncer
CN110072550A (zh) * 2016-11-01 2019-07-30 德那翠丝有限公司 用于治疗脑癌的组合疗法
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
CN108261426B (zh) * 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
CA3048313A1 (en) * 2017-01-06 2018-07-12 Stabilitech Biopharma Ltd Virus
US11338003B2 (en) 2017-04-14 2022-05-24 Cg Oncology, Inc. Methods of treating bladder cancer with an oncolytic virus
NZ758626A (en) 2017-04-21 2023-09-29 Baylor College Medicine Oncolytic virotherapy and immunotherapy
IL270876B2 (en) 2017-05-25 2024-06-01 Univ Central Florida Res Found Inc Novel oncolytic viruses to induce tumor cell killing by natural killer cells
CN111542601A (zh) * 2017-11-08 2020-08-14 国立大学法人鹿儿岛大学 确保安全并且能够有效地治疗甚至转移性癌症的、具有提供装载的免疫诱导基因的最佳表达水平的表达控制系统的肿瘤溶解性病毒(肿瘤溶解性免疫治疗)
EP3725888A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing peptidylarginine deiminase and tissue inhibitor of metalloproteinase
EP3725323A1 (en) 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
EP3725322A1 (en) 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing granzyme and perforin
WO2021194183A1 (ko) * 2020-03-25 2021-09-30 ㈜큐리진 면역 회피성 항종양 아데노바이러스
CN111909962A (zh) * 2020-07-23 2020-11-10 药鼎(北京)国际细胞医学技术有限公司 一种治疗肝癌的病毒构建体及其用途和构建方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE454445T1 (de) * 1998-11-10 2010-01-15 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
DE60018920T2 (de) * 1999-06-01 2006-04-13 University Of Washington, Seattle Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration
EP1228234A2 (en) * 2000-03-14 2002-08-07 Neurologix, Inc. Production of chimeric capsid vectors
AU2003265873A1 (en) * 2003-08-28 2005-04-14 Cell Genesys, Inc. Oncolytic adenoviral vectors encoding gm-csf
ES2276623B1 (es) * 2005-12-12 2008-06-01 Proyecto De Biomedicina Cima, S.L Nuevos adenovirus recombinantes de replicacion condicionada (crad).
WO2007103825A2 (en) * 2006-03-02 2007-09-13 The Board Of Regents Of The University Of Texas System Combination therapy with oncolytic adenovirus

Also Published As

Publication number Publication date
KR101761094B1 (ko) 2017-08-04
LT2379586T (lt) 2017-03-10
WO2010072900A1 (en) 2010-07-01
SG173432A1 (en) 2011-09-29
ZA201104224B (en) 2012-09-26
JP2012513209A (ja) 2012-06-14
AU2009332883A1 (en) 2011-07-07
JP6280084B2 (ja) 2018-02-14
PT2379586T (pt) 2017-02-09
CA2748180A1 (en) 2010-07-01
HUE031689T2 (en) 2017-07-28
SI2379586T1 (sl) 2017-02-28
RU2520823C2 (ru) 2014-06-27
DK2379586T3 (en) 2017-02-06
EP2379586A1 (en) 2011-10-26
KR20110096579A (ko) 2011-08-30
ES2612889T3 (es) 2017-05-19
AU2009332883B2 (en) 2015-05-21
CN102264760A (zh) 2011-11-30
CY1120039T1 (el) 2018-12-12
JP2016019530A (ja) 2016-02-04
RU2011130511A (ru) 2013-01-27
BRPI0924123B8 (pt) 2021-05-25
CA2748180C (en) 2017-06-20
EP2379586B1 (en) 2016-11-02
CN102264760B (zh) 2017-03-22
BRPI0924123B1 (pt) 2020-10-20
HRP20170165T1 (hr) 2017-04-07

Similar Documents

Publication Publication Date Title
HRP20170165T1 (hr) Onkolitički adenovirusni vektori i metode i uporabe u vezi s time
ZA201301862B (en) Oncolytic adenoviral vectors and methods and uses related thereof
HK1141541A1 (zh) 溶瘤痘病毒向量
HK1141314A1 (en) Poxviral oncolytic vectors
ZA201004736B (en) Improved mammalian expression vectors and uses thereof
EP2344648A4 (en) RECOMBINANT VECTORS
IL210804A (en) Benzylidenehydrazides and their uses
EP2234104A4 (en) VECTOR QUANTIFIER, REVERSE VECTOR QUANTIFIER, AND METHODS THEREFOR
GB0810912D0 (en) Vector
ZA201005866B (en) Closterovirus vectors and methods
ZA201103456B (en) Leukolectins and uses thereof
EP2291377A4 (en) IMIDAZOPYRIMIDINONE AND ITS USES
GB0820631D0 (en) Vectors
PL2274422T3 (pl) Wektor ekspresyjny
ZA201103960B (en) An expression vector and processes thereof
EP2247601A4 (en) THIAZOPYRIMIDINONE AND APPLICATIONS THEREOF
ZA201100019B (en) Variant hhip1 protein and methods and uses thereof
EP2285827A4 (en) PEPTIDES AND ITS USE
GB0810154D0 (en) Expression vector
EP2154246A4 (en) VIRAL VECTOR AND ITS USE
GB0800502D0 (en) Peptides and their uses
GB0816561D0 (en) Peptides and uses thereof
GB0823425D0 (en) Vectors
GB0810609D0 (en) Methods and uses
GB0816523D0 (en) Methods and uses